300683 海特生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-0.923-5.046-0.6051.371-1.450
总资产报酬率 ROA (%)-0.767-4.256-0.5191.132-1.149
投入资产回报率 ROIC (%)-0.841-4.602-0.5541.211-1.248

边际利润分析
销售毛利率 (%)45.77342.70948.46556.92259.154
营业利润率 (%)-10.114-23.755-0.9913.472-6.692
息税前利润/营业总收入 (%)-10.963-26.421-2.7691.288-10.913
净利润/营业总收入 (%)-8.587-21.293-1.1474.883-4.899

收益指标分析
经营活动净收益/利润总额(%)191.71473.68633.17662.3556.107
价值变动净收益/利润总额(%)-34.569-11.570-303.11568.468-33.814
营业外收支净额/利润总额(%)2.3195.86412.800-4.3216.135

偿债能力分析
流动比率 (X)4.0924.2995.0726.3493.616
速动比率 (X)3.7123.9604.6506.0623.427
资产负债率 (%)16.63716.01113.73213.14021.112
带息债务/全部投入资本 (%)3.0655.1826.8086.115--
股东权益/带息债务 (%)2,979.4471,756.5151,342.0071,498.597755.296
股东权益/负债合计 (%)497.901520.916621.573655.765370.143
利息保障倍数 (X)18.00322.2831.696-0.6312.885

营运能力分析
应收账款周转天数 (天)32.40034.29341.73262.1720.000
存货周转天数 (天)140.069123.94397.30096.0420.000